<DOC>
	<DOCNO>NCT02342223</DOCNO>
	<brief_summary>The purpose study test safety Voluma see effect HIV facial lipoatrophy . The hypothesis Voluma safe , efficacious positively impact quality-of-life treatment facial lipoatrophy patient HIV .</brief_summary>
	<brief_title>Voluma Filler Agent For The Treatment HIV-associated Facial Lipoatrophy</brief_title>
	<detailed_description>HIV facial lipoatrophy ( volume loss ) increase concern patient Highly Active Anti-Retroviral Therapy ( HAART ) affect quality-of-life adherence medication regimen . Treatment HIV facial lipoatrophy help improve patient wellness remove social stigma associate HIV facial lipoatrophy . Currently , medical therapy treat HIV facial lipoatrophy FDA-approved indication . Juv√©derm Voluma ( Allergan ) may benefit patient HAART may provide immediate aesthetic enhancement potentially few adverse effect , result natural appear facial enhancement outcome . Voluma agent FDA-approved facial volume loss . We anticipate Voluma less adverse effect current FDA-approved drug HIV lipoatrophy Voluma hyaluronic acid ( HA ) -based agent . The benefit use hyaluronidase `` correct '' `` modify '' facial HA-based volume therapy also benefit HIV patient , currently exist post-injection modification option FDA-approved filling agent use treat patient HIV facial lipoatrophy . Voluma currently FDA-approved correction age-related volume loss midface , 's alteration chemical biophysical property Voluma use propose study . In addition conventional injection technique , implement 'smile fill ' technique pioneer clinical research group achieve good mid-face aesthetic outcome .</detailed_description>
	<mesh_term>Facies</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Aged 18 year laboratory evidence HIV1 infection HAART therapy least 1 ( one ) year . Not AIDS ( CD4 count &lt; 250 ) AIDSdefining illness . Bilateral lipoatrophy correspond visual grade 2 attached Carruthers Lipoatrophy Severity Scale ( CLSS ) . Available willing attend study followup visit . Able willing give inform consent . Any active skin inflammation infection near treatment area . Hypersensitivity component Voluma . Previous treatment Voluma product facial lipoatrophy within past year . Has know bleed disorder History keloid formation Currently receive systemic corticosteroid anabolic steroid Currently know anticoagulant ( i.e . aspirin , nonsteroidal antiinflammatory drug ) Pregnancy breastfeed anticipate become pregnant study period . Any excluding factor , accord investigator 's judgment , would preclude enrollment study . Any condition may interfere ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>human immunodeficiency virus</keyword>
	<keyword>facial lipoatrophy</keyword>
	<keyword>facial lipodystrophy</keyword>
	<keyword>hyaluronic acid</keyword>
	<keyword>dermal filler</keyword>
	<keyword>filler agent</keyword>
</DOC>